Global Medical Cannabis Market Trends, Growth and Size Analysis By Product form (Powders, Solids, Ointments and creams, Oil, Others), By Derivative (Cannabidiol, Tetrahydrocannabinol), By Application (Arthritis, Cancer, Alzheimer’s Disease, Others) and By Distribution Channel (Retail pharmacy, Online stores, Others) – Forecast to 2027
Market Overview
The global medical cannabis market is anticipated to acquire a market value of USD 52.35 billion while thriving at a CAGR of 15.4% during the forecast period, anticipated Market Research Future (MRFR). Medical cannabis is the most commonly prescribed treatment for cancer, arthritis, and others.
The increasing approval for medical cannabis products is anticipated to be a significant factor that can grow the market during the forecast period. The increasing R&D activities and the rising incidents of chronic ailments among expanding populace are anticipated to grow the market in the coming time. On the contrary, the growing usage of cannabis for recreational purposes can bring a negative impact to the human health, which is expected to affect the market significantly.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8368
Market Segmentation
The global medical cannabis market is segmented into derivative, application, product form, and distribution channel.
The derivative-based segments of the global medical cannabis market are cannabidiol (CBD) and tetrahydrocannabinol (THC). The CBD segment is anticipated to acquire a majority of market share during the forecast period.
The application-based segments of the global medical cannabis market are cancer, schizophrenia, arthritis, Alzheimer’s disease, and others. Among all, Alzheimer’s disease is anticipated to procure the largest market share in the assessment tenure.
The product-form based segments of the global medical cannabis market are powders, solids, ointments and creams, oil, and others. Among all, the powders segment is anticipated to be the fastest-growing segment during the analysis period.
The distribution channel form-based segments of the global medical cannabis market are retail pharmacy, online stores, and others. Among all, the retail pharmacy segment is anticipated to procure the largest market share during the forecast period.
Regional Analysis
As per the assessment conducted by MRFR, the Americas is anticipated to be the largest market share during the forecast period. The increasing participation of players in the region is likely to make a significant contribution to developing the market of North America. The increasing agreement among key players is anticipated to play a salient role in driving the regional market. Recently, a global pioneer in cannabis research, production, and distribution, Tilray, announced that it has agreed with Worldpharma Biotech, through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda, to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. In another news, a biopharmaceutical company focused on the development of cannabis products, Avicenna, has announced that the company has entered into an agreement with Harrington Wellness Inc. for the commercialization of CBD tropical product line targeting athletes and active consumers in Canada and the US. Various companies are legalizing the application of cannabis for manufacturing drugs owing to the rising demand for the application of cannabis in the medical field. On the other hand, APAC is anticipated to be the fastest-growing region due to the increasing legalization of medical cannabis in the region. Developing countries such as; India and China are expected to make a significant contribution in developing the market in the assessment tenure.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/medical-cannabis-market-8368
Key Players
Some of the renowned players of the global medical cannabis market are Aphria, Inc. (Canada), Canopy Growth Corporation (Canada), Maricann Inc. (Canada), GW Pharmaceuticals PLC (UK), Tilray (Canada), Medical Marijuana, Inc. (US), Aurora Cannabis (Canada), Cannabis Sativa Inc. (US), CanniMed Ltd (Canada), United Cannabis (US), MediPharm Labs (Canada), and GBSciences Inc. (US).
You may also be interested in..
Human Genetics Market Research Report - Global Forecast to 2027
Syringe and Needle Market Research Report - Global Forecast to 2027
Global Microbial Products Market Report - Forecast to 2027
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Market Overview The global medical cannabis market is anticipated to acquire a market value of USD 52.35 billion while thriving at a CAGR of 15.4% during the forecast period, anticipated Market Research Future (MRFR).
Medical cannabis is the most commonly prescribed treatment for cancer, arthritis, and others.Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/8368The increasing approval for medical cannabis products is anticipated to be a significant factor that can grow the market during the forecast period.
The increasing R activities and the rising incidents of chronic ailments among expanding populace are anticipated to grow the market in the coming time.
Market Segmentation The global medical cannabis market has been segmentedbased on product type, derivative, route of administration, application, and distribution channel.The market, based on product type, has been segregated into solid, dissolvable/powders, oil, and ointment & creams.On the basis of derivative, the market is bifurcated into cannabidiol and tetrahydrocannabinol.Based on route of administration, the global medical cannabis market has been segmented into inhalation, oral, and topical.Based on application it is divided into pain management, neurological health management, and mental health management.
The inhalation segment dominated the market segment is expected to register the fastest growth in the application segment of the global medical cannabis market during the forecast period.
Recently, a global pioneer in cannabis research, production, and distribution, Tilray, announced that it has agreed with Worldpharma Biotech, through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda, to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain.
Global Medical Cannabis Market Trends, Growth and Size Analysis By Product form (Powders, Solids, Ointments and creams, Oil, Others), By Derivative (Cannabidiol, Tetrahydrocannabinol), By Application (Arthritis, Cancer, Alzheimer’s Disease, Others) and By Distribution Channel (Retail pharmacy, Online stores, Others) – Forecast to 2027Overview:The global market report covering the Medical Cannabis market revealed an opportunity for the market to score a valuation of USD 52.35 Billion by 2025.
This would happen with a CAGR of 15.4% CAGR between 2019 and 2025, which as per Market Research Future (MRFR) is the forecast period.
Increasing instances of chronic diseases and other severe medical conditions can inspire better market growth in the coming years.
The growth of the market for medical cannabis can also inspire illegal practitioners taking advantage of the system, which can hold back the smooth growth in the coming years.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8368 SegmentationThe global market report on medical cannabis includes studies on the application, derivative, product form, and distribution channel.
By product form, the global market report covers the medical cannabis market by having it segmented into solids, oil, ointments & creams, powders, and others.
Alzheimer’s Disease has the largest segment, whereas, the cancer segment can produce a high growth rate in the coming years.By distribution channel, the report on the global market for medical cannabis covers online stores, retail pharmacies, and others.
Global Medical Cannabis Market Research Report: By Product form (Powders, Solids, Ointments and creams, Oil, Others), By Derivative (Cannabidiol, Tetrahydrocannabinol), By Application (Arthritis, Cancer, Alzheimer’s Disease, Others) and By Distribution Channel (Retail pharmacy, Online stores, Others) – Forecast to 2027 Medical Cannabis Market HighlightsAccording to Market Research Future (MRFR), the global medical cannabis market is estimated to procure a market value of USD 52.35 billion while thriving at a CAGR of 15.4% by 2025.The increasing legalization of the hemp plant in various countries for medicinal purposes is projected to provide lucrative opportunities to pharmaceutical companies, which may strengthen the global market.
The ability of the herbal plant to provide relief from chronic pain, vomiting, and sleep difficulties can accelerate the demand for medical marijuana, which may boost the industry in the coming period.
Furthermore, the growing usage of cannabis to prevent cancer is likely to surge the demand for herbal leaves that can fuel the trade in the coming period.On the other hand, the increasing usage of weed as recreational cannabis can lead to adverse human health, which is anticipated to hinder the market growth.
However, the capability of cannabis to fight depression is likely to counter the impeding factor that can underpin global trade.Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/8368Market Segmentation The segmental analysis of the global medical cannabis market is done by application, end-user, derivative, and product form.The application-based segments of the global medical cannabis market are arthritis, cancer, Alzheimer’s disease, schizophrenia, and others.
Among all segments, the Alzheimer’s disease segment is anticipated to acquire the largest market share during the forecast period.The end-user based segments of the global medical cannabis market are retail pharmacy, online stores, and others.
Among all segments, the retail pharmacy segment is expected to acquire the largest market share during the review period.The derivative-based segments of the global medical cannabis market are cannabidiol (CBD) and tetrahydrocannabinol (THC).
Medical Nutrition Market Share Research Analysis by Type (Pediatric Nutrition, Parenteral Nutrition, Elderly Nutrition and Sport Nutrition), by Product Type (Amino Acid Solution, Multiple Vitamins and Antioxidants, Lipid Emulsion, Trace Elements and Chamber Bags), by Route of Administration (Parenteral and Oral), by Application (Pediatric Malnutrition, Gastrointestinal Diseases, Renal Failure, Cancer, Pulmonary Diseases, Diabetes and Neurological Diseases), by Distribution Channel (Hospitals, Compounding Pharmacy, Retail Pharmacy and E-Commerce Websites) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) – Global Forecast till 2023The “Medical Nutrition Market Share ” In-Depth competition analysis of the major companies in the report, sector of the report includes the market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue.The Global Medical Nutrition Market Share is expected to reach to the market value of USD 52,395.3 million by 2023 from USD 41, 014.8 million in 2017, and is expected to grow at CAGR of 5.0% during the forecast period from 2018 to 2023.The Medical Nutrition Market Share Free Growth Sample will provide valuable insight with an emphasis on the global market including some of the major players such As, Nestle Health Science, Baxter Healthcare Corporation, Sanofi, Pfizer Inc., Abbott Nutrition, GlaxoSmithKline PLC (GSK), Mead Johnson Nutrition Company, Bayer AG, Danone Nutricia, Danisco (DuPont), Grifols SA, B. Braun Melsungen AG, and Fresenius Kabi AG.For Market Medical Nutrition Market Share analysis, the report covers upstream raw materials, equipment, downstream client survey, Marketing channels, Market development trend and proposals, which more specifically include valuable information By key applications and consumption, key regions and consumption, key Global distributors , major raw materials suppliers and contact information, major manufacturing equipment suppliers and contact information, major suppliers and contact Information, key consumers and contact information, and supply.Medical Nutrition Market Share Segment by Regions, regional analysis covers:North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia etc.
)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)Access Complete Detailed TOC Research Report at https://www.marketresearchfuture.com/reports/medical-nutrition-market-1330The report also appraises the supervisory scenarios which affect various decisions in the market.
With all the data congregated and scrutinized using SWOT analysis, there is a vibrant picture of the competitive scenario of the Global Medical Nutrition Market Share.
Openings for the future market growth were uncovered and preoccupied competitive threats also textured.About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.Contact:Market Research Future+1 646 845 9312Email: [email protected]
Key PlayersSome of the key players in the Global Antiemetics Market are GSK (UK), Merck (US), Sanofi-Aventis (France), Pfizer Inc. (US), Mylan (US), Eli Lilly and Company (US), Johnson & Johnson (US), Baxter International (US), Dr. Reddy's Laboratories Inc. (India) and others.Market HighlightsAccording to MRFR analysis, Antiemetics Market is expected to register a CAGR of 6.6% during the forecast period of 2019 to 2025 and account for USD 6.7 Billion in 2025.The Global Antiemetics Market is expected to grow at a steady pace.
There are numerous antiemetics agents available for the treatment of nausea and vomiting, including; dopamine antagonists, anticholinergics, antihistamines, serotonin antagonists, and others.
According to a study, it is found that PONV occurs in nearly 30% of the general surgical population and up to 70% to 80% of high-risk surgical patients.
Europe is expected to account for the second-largest market in the global antiemetics market owing to well-developed research infrastructure, increasing healthcare awareness in the region, and high expenditure in pharmaceutical research.SegmentationThe Global Antiemetics Market has been segmented into agents, drug type, application, and distribution channel.By agents, the market has been segmented into dopamine antagonists, anticholinergics, antihistamines, serotonin antagonists, cannabinoids, and others.
Dopamine accounted for the largest market share majorly due to FDA approval for the maximum number of applicationBy drug type, the market is segmented into prescribed and OTC.
Asia-Pacific is expected to be the fastest-growing region due to the growing interest of major key players in entering emerging markets, increasing development in the pharmaceutical industry in this region.
Market Highlights:Global Migraine Drugs Market Research Report: By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2025According to MRFR analysis, the global migraine drugs market is expected to register a CAGR of 5.9% during the forecast period of 2019 to 2025 and was valued at USD 4.4 billion in 2018.Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds.
Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels.
However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for migraine are the factors that are expected to limit the growth of the global migraine drugs market during the forecast period.Market Key Players:Some of the key players in the global migraine drugs market are Allergan Plc (Ireland), Alder Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca Plc (UK), Johnson & Johnson Services, Inc. (US), Amgen Inc (US), Eli Lilly and Company, and eNeura Inc.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8379 Segmentation:The global migraine drugs market has been segmented based on type, treatment, drug class, and end user.The global migraine drugs market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine.The global migraine drugs market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others.The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine.The global migraine drugs market has been segmented, on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.Triptons are the most preferred type of drugs class for migraine patients due to its high efficacy.
The retail pharmacy segment offers over the counter (OTC) and prescription migraine drugs though a chain of pharmacies globally.
Other end users include online pharmacy segment that offers OTC migraine drugs through e-commerce platforms.Regional Analysis:The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is expected to be the largest market owing to the increasing prevalence of migraine and R by major players in the region.
For instance, in September 2018, Eli Lilly and Company launched Emgality (galcanezumab-gnlm) injection (300 mg) for the preventive treatment of migraine in adults.
